This study suggests that the GFIPO-induced activation of TNFα and TGFβ pathways, coupled with the previously mentioned disruption in lipid metabolism, is implicated in the advancement of MASLD, characterized by liver inflammation and the development of fibrosis. This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.